Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T induced resistance in ALL

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

Key clinical point: Unintentional transduction of a single leukemic B cell induced resistance to CTL019 (tisagenlecleucel) therapy.

Major finding: A patient with B-cell acute lymphoblastic leukemia (B-ALL) had frank relapse 9 months after a CTL019 infusion, with more than 90% bone marrow infiltration of chimeric antigen receptor–transduced B-cell leukemia cells.

Study details: A case study of a 20-year-old male with B-ALL undergoing CTL019 therapy.

Disclosures: Study funding was provided by Bristol-Myers Squibb, Novartis, the National Institutes of Health, and others. Dr. Ruella and several of his colleagues work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research and are inventors of intellectual property licensed by the University of Pennsylvania to Novartis.

Read the article here.

Citation:

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9.

Must Reads in Leukemia, Myelodysplasia, Transplantation

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

Cochrane on Bisphosphonates in Multiple Myeloma, Cochrane; 2017 Dec 18; Mhaskar, Kumar, et al

Venetoclax Regimens Assessed in Patients with AML, Am J Hematol; ePub 2017 Dec 23; DiNardo, et al

Encourage This Behavior in Childhood ALL Survivors, Cancer; ePub 2017 Dec 4; Howell, Wilson, et al

Prognostic Testing Patterns, CLL Outcomes Assessed, Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 5; Mato, et al